What Google's policy on speculative and experimental treatments covers
Google Ads maintains a policy restricting advertising for speculative and experimental medical treatments, including cell therapies and gene therapies, in the United States. The policy exists separately from any FDA action; an ad can violate it regardless of what a product's federal regulatory status turns out to be.
Because the category is defined broadly around cell therapies, campaigns referencing Wharton's jelly allografts or exosome products for clinical use can fall inside scope even when the business never uses the phrase "stem cell therapy" directly.
Why this touches both clinics and distributors, not only obvious offenders
An ad does not need to make a disease claim to run into this policy. Describing a procedure involving these product categories in a way that reads as offering the therapy can be enough on its own. Distributor ads promoting the same product categories carry the same exposure as clinic ads.
This matters for budget planning. A campaign built around this category can be paused, or an account can be reviewed, with little warning, so a media plan that depends entirely on paid search for this audience carries platform risk on top of the regulatory considerations covered elsewhere in this library.
How this overlaps with, but isn't identical to, FDA's view of marketing
FDA treats marketing content as evidence of a product's intended use. Google's policy is a separate, platform-level restriction on what can be advertised at all. A clinic can satisfy one framework and still have a problem with the other, because the two are asking different questions, one about platform advertising rules and one about federal regulatory status.
If ad copy is written to avoid disease and outcome claims for FDA purposes, review that same copy against this Google policy separately. Satisfying one framework does not guarantee satisfying the other.
Channels to evaluate when paid search is restricted
When evaluating any outreach channel, review its policy and proposed content against the applicable rules.
No channel recommendation here establishes permission to advertise these products. Review the applicable policy before publishing.
- Direct account relationships verified by NPI number rather than consumer-facing lead forms
- Peer-to-peer conversations about product documentation rather than promotional claims
- Organic content written for licensed professionals rather than consumer search terms
Keeping claims discipline consistent across channels
Because Google's enforcement and FDA's enforcement both read marketing content as evidence, the same checklist used for a website or sales deck should apply to any ad copy that is approved to run: no disease names, no efficacy or outcome language, no superlatives, and a clear audience restriction to licensed professionals.
This article summarizes platform policy; it is not legal advice. Review current policy text and claims with the regulatory counsel who handles other marketing review here.
Frequently asked questions
Does Google's policy only apply to ads that mention "stem cells" by name?+
No. The policy is written broadly around speculative and experimental cell and gene therapies, so ad copy can fall within scope without using that exact phrase.
Can we advertise a Wharton's jelly product under this policy if we avoid disease claims?+
Avoiding disease claims reduces risk but does not guarantee compliance on its own. Review current policy text directly and consult counsel before running ads referencing these product categories.
If our ad is FDA-compliant, is it automatically Google-Ads-compliant?+
No. These are separate frameworks asking different questions. An ad can meet one standard and still be restricted or rejected under the other.
What's a lower-risk channel for reaching licensed buyers in this category?+
No channel recommendation here establishes permission to advertise these products. Review the applicable policy for any channel, including direct outreach and organic content, before publishing, and confirm with counsel before running paid campaigns referencing these product categories.